Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Tax Provisions: 2017-2025

Historic Tax Provisions for Corcept Therapeutics (CORT) over the last 9 years, with Sep 2025 value amounting to -$4.4 million.

  • Corcept Therapeutics' Tax Provisions fell 177.23% to -$4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.7 million, marking a year-over-year decrease of 172.16%. This contributed to the annual value of $20.3 million for FY2024, which is 10.14% up from last year.
  • Corcept Therapeutics' Tax Provisions amounted to -$4.4 million in Q3 2025, which was down 26.43% from -$3.5 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Tax Provisions registered a high of $7.7 million during Q4 2022, and its lowest value of -$10.9 million during Q1 2025.
  • For the 3-year period, Corcept Therapeutics' Tax Provisions averaged around $1.8 million, with its median value being $5.0 million (2023).
  • Per our database at Business Quant, Corcept Therapeutics' Tax Provisions skyrocketed by 412.16% in 2023 and then slumped by 251.14% in 2025.
  • Over the past 5 years, Corcept Therapeutics' Tax Provisions (Quarterly) stood at $4.7 million in 2021, then soared by 63.85% to $7.7 million in 2022, then declined by 29.40% to $5.4 million in 2023, then tumbled by 78.14% to $1.2 million in 2024, then plummeted by 177.23% to -$4.4 million in 2025.
  • Its last three reported values are -$4.4 million in Q3 2025, -$3.5 million for Q2 2025, and -$10.9 million during Q1 2025.